Organization | Ludaopei Hospital

Ludaopei Hospital Report issue

Academic/Hospital Phase 1 Phase 2

Founded: Beijing China (1964)

Organization Overview

First Clinical Trial

2018

NCT03574168

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2020

Timeline

NOW

Now

Alternative names

Beijing Ludaopei Hospital | Hebei Yanda Ludaopei Hospital

Active Ingredients

Drugs in Phase 2 Trials (1)

cd22 car-t cells (2 trials)

Drugs in Phase 1 Trials (11)

allogeneic natural killer cells (1 trial)

bcma car-t cells (1 trial)

bcma/cd19 dual-target car-t (1 trial)

cd123 car-t cells (1 trial)

cd19 car-t cells (8 trials)

cd19/cd20 bispecific car-t cells (2 trials)

cd19/cd22-dual-star-t (1 trial)

cmv-specific t-cells (1 trial)

ebv-tcr-t cells (1 trial)

gc007f (1 trial)

gc022 (3 trials)

Drugs in Other Trials (6)

bcma-pd1-cart cell (1 trial)

car-γδt (1 trial)

cd7 car-t cell (1 trial)

rd13-01 (1 trial)

senl-h19 car-t (1 trial)

senl-t7 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Communicable Diseases (Phase 1)

Cytomegalovirus Infections (Phase 1)

Infections (Phase 1)

Leukemia (Phase 1)

Leukemia, B-Cell (Phase 1)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)

Leukemia, Lymphoid (Phase 1)

Leukemia, Myeloid (Phase 1)

Leukemia, Myeloid, Acute (Phase 1)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 1)

Multiple Myeloma (Phase 1)

Neoplasm, Residual (Phase 1)

Neoplasms (Phase 1)

Neoplasms, Plasma Cell (Phase 1)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Virus Diseases (Phase 1)

Overview

Highest Phase: Phase 2
# of Trials: 29
# of Trial APIs: 18